Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth

J Pathol. 2018 Dec;246(4):447-458. doi: 10.1002/path.5152. Epub 2018 Oct 30.

Abstract

Aggressive tumor cells can adopt an endothelial cell-like phenotype and contribute to the formation of a tumor vasculature, independent of tumor angiogenesis. This adoptive mechanism is referred to as vascular mimicry and it is associated with poor survival in cancer patients. To what extent tumor cells capable of vascular mimicry phenocopy the angiogenic cascade is still poorly explored. Here, we identify pericytes as important players in vascular mimicry. We found that pericytes are recruited by vascular mimicry-positive tumor cells in order to facilitate sprouting and to provide structural support of the vascular-like networks. The pericyte recruitment is mediated through platelet-derived growth factor (PDGF)-B. Consequently, preventing PDGF-B signaling by blocking the PDGF receptors with either the small tyrosine kinase inhibitor imatinib or blocking antibodies inhibits vascular mimicry and tumor growth. Collectively, the current study identifies an important role for pericytes in the formation of vascular-like structures by tumor cells. Moreover, the mechanism that controls the pericyte recruitment provides therapeutic opportunities for patients with aggressive vascular mimicry-positive cancer types. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Keywords: Ewing sarcoma; cancer; endothelial cells; imatinib; melanoma; perivascular cells; tumor angiogenesis; vasculogenic mimicry; vessel stabilization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Immunological / pharmacology*
  • Biological Mimicry / drug effects*
  • Cell Communication / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Coculture Techniques
  • Humans
  • Imatinib Mesylate / pharmacology*
  • Melanoma, Experimental / blood supply*
  • Melanoma, Experimental / drug therapy*
  • Melanoma, Experimental / metabolism
  • Melanoma, Experimental / pathology
  • Mice
  • Mice, Nude
  • Neovascularization, Pathologic*
  • Pericytes / drug effects*
  • Pericytes / metabolism
  • Pericytes / pathology
  • Platelet-Derived Growth Factor / antagonists & inhibitors*
  • Platelet-Derived Growth Factor / immunology
  • Platelet-Derived Growth Factor / metabolism
  • Protein Kinase Inhibitors / pharmacology*
  • Signal Transduction / drug effects
  • Time Factors
  • Tumor Burden / drug effects
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents, Immunological
  • Platelet-Derived Growth Factor
  • Protein Kinase Inhibitors
  • Imatinib Mesylate